Settlements Moving Forward in Actos® Bladder Cancer Lawsuits
The diabetes drug, Actos®, has been linked to the development of bladder cancer in some patients. Many victims are seeking compensation for their losses with lawsuits against the maker of the drug. Now, many of those cases are beginning to come to a close.
In April, Takeda Pharmaceutical, Inc. offered more than $2 billion to settle a majority of the Actos bladder cancer lawsuits. It didn’t seem as though the deal would be closed in August, considering only 75 percent of the victims had agreed to the terms of the settlement. However, the company announced last month that they had reached settlements with 96 percent of the drug’s victims for an estimated $2.4 billion. This laid to rest seven of the nine remaining lawsuits the company is facing in connection with Actos bladder cancer cases.
Now, it seems as though another of those cases has been settled as well. Fierce Pharma reports a case involving to Nevada patients who developed bladder cancer after using Actos® has been settled. The terms of the agreement were not disclosed.
At Lowell Stanley Injury Lawyers, we are aware of the struggles many Actos bladder cancer victims face along their road to recovery. That’s why our drug injury lawyers are hopeful the settlements reached in these cases brings a sense of closure to those whose lives were affected by the dangers of the drug.